Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.52 |
| ▸ | USP2 | O75604 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MLYCD | O95822 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6418198 | 0.89 | TSHR (0.60) | TSHRALDH1A1LMNAMAPK1USP2 | |
| SCHEMBL6263375 | 0.88 | LMNA (0.57) | TSHRALDH1A1LMNAMAPK1USP2 | |
| SCHEMBL6261073 | 0.88 | TSHR (0.56) | TSHRALDH1A1LMNAMAPK1USP2 | |
| SCHEMBL6263738 | 0.88 | TSHR (0.56) | TSHRALDH1A1LMNAMAPK1USP2 | |
| SCHEMBL6263789 | 0.87 | LMNA (0.58) | TSHRALDH1A1LMNAMAPK1USP2 | |
| SCHEMBL6416255 | 0.85 | TSHR (0.65) | TSHRALDH1A1LMNAMAPK1USP2 | |
| SCHEMBL6263773 | 0.85 | TSHR (0.55) | TSHRALDH1A1LMNAMAPK1USP2 | |
| SCHEMBL6415443 | 0.85 | TSHR (0.59) | TSHRALDH1A1LMNAMAPK1USP2 | |
| SCHEMBL6415048 | 0.84 | KMT2A (0.62) | TSHRALDH1A1LMNAMAPK1USP2 | |
| SCHEMBL6262956 | 0.84 | TSHR (0.58) | TSHRALDH1A1LMNAMAPK1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1590329-A1 | N-ARYL HETEROAROMATIC PRODUCTS, COMPOSITIONS CONTAINING SAME AND USE THEREOF | Aventis Pharma S.A. (FR) | 2005-11-02 | — | — | EP | disclosed |
| US-20050130989-A1 | N-arylheteroaromatic products compositions containing them and use thereof | AVENTIS PHARMA S. A. (FR) | 2005-06-16 | — | — | US | disclosed |
| WO-2004078732-A1 | N-ARYL HETEROAROMATIC PRODUCTS, COMPOSITIONS CONTAINING SAME AND USE THEREOF | AVENTIS PHARMA S.A. (FR) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130989-A1 | N-arylheteroaromatic products compositions containing them and use thereof | AHR, NQO1, ARNT | TSHR 4236/4885ALDH1A1 360/4885LMNA 2233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.